A Food and Drug Administration panel has voted – unanimously – to recommend approval of a double chin-reducing injectable drug, the The Wall Street Journal reports.
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S. Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support the approval of ATX-101 (deoxycholic acid) injection for improvement in the appearance of moderate t...
Also read: Russia's FG Budushchee rises in market debut
05:47 Samsung's smartphone share hit by Note7 debacle, stiff competition22
20:52 After earning crush, Tesla expected to unveil 'solar roof', integrated home battery40
13:03 Waste Management 3rd-quarter earnings rise 11 percent11
18:37 Sumner Redstone forced to borrow $100 million from National Amusements: lawsuit13